Patents Examined by Abigail Vanhorn
-
Patent number: 11970694Abstract: Provided are linkers suitable for preparing a conjugate of a nucleic acid and a peptide as a translation product thereof in a reconstituted cell-free translation system in genotype-phenotype mapping (display methods), said linkers comprising a single-stranded structure region having a side chain base pairing with the base at the 3?-end of an mRNA at one end and a peptidyl acceptor region containing an amino acid attached to an oligo RNA consisting of a nucleotide sequence of ACCA via an ester bond at the other end, characterized in that the ester bond is formed by using an artificial RNA catalyst. Also provided are display methods using [mRNA]-[linker]-[peptide] conjugates assembled via such linkers.Type: GrantFiled: March 3, 2020Date of Patent: April 30, 2024Assignee: PeptiDream Inc.Inventors: Kenji Kashiwagi, Patrick Reid
-
Patent number: 11963527Abstract: The disclosure provides for methods of repelling, directing, altering the behavior, and controlling an insect by utilizing a compound or composition described herein. The disclosure also provides for methods of promoting the health of an insect by repelling a pest that preys on insect and/or by providing an antibiotic or nutritional supplement composition to an insect. The disclosure also provides for a composition including at least one repelling, controlling, or directing compound or composition described herein together with an insecticide, herbicide, fungicide, or miticide. Compounds, compositions, seeds, and plants useful in these methods are also described.Type: GrantFiled: December 10, 2018Date of Patent: April 23, 2024Assignee: BASF CorporationInventors: Tai-Teh Wu, Dick Rogers, Jian Zhang, Chi Yu Roy Chen, Robert Croft, Ronald Reichert, William G. Hairston
-
Patent number: 11938247Abstract: Provided are a method for fabricating a human nasal turbinate-derived mesenchymal stem cell-based 3D bioprinted construct, and a use thereof, wherein the human nasal turbinate-derived mesenchymal stem cell-based, 3D bioprinted construct is advantageous over conventional mesenchymal stem cell-based, 3D bioprinted constructs in that the former can survive and proliferate stably in vitro and/or in vivo and shows high osteogenic differentiation ability as well, therefore is expected to make a great contribution to the practical use of cellular therapeutic agents.Type: GrantFiled: May 2, 2018Date of Patent: March 26, 2024Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Sung Won Kim, Jung Yeon Lim, Sun Hwa Park, Byeong Gon Yoon, Dong-Woo Cho, Jinah Jang, Seok Won Kim
-
Patent number: 11931328Abstract: Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts.Type: GrantFiled: March 16, 2023Date of Patent: March 19, 2024Assignee: AMNEAL PHARMACEUTICALS LLCInventors: David Penake, Sharon Hamm, Leonard O'Mahony, John Devane, Wolfgang Mohr, Manuel Weinheimer
-
Patent number: 11925686Abstract: The present invention relates to a medicinal material for light therapy, comprising a matrix material and a photosensitizer, wherein the photosensitizer is dispersed inside the matrix material by copolymerization, is mixed inside the matrix material, or attached to the surface of the matrix material by surface grafting, modification, coating and the like. The present material can kill diseased tissue cells with a radiation under selected wavelength so as to obtain a phototherapy treatment of ophthalmic diseases. The present invention also provides a process for preparing the material and a use in preparing an ophthalmic medical device.Type: GrantFiled: July 22, 2016Date of Patent: March 12, 2024Assignee: EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.Inventors: Xince Sui, Yongji Wei, Jiangbing Xie
-
Patent number: 11925725Abstract: An extracellular matrix (ECM) mixture and ECM scaffolds made with same are disclosed. The ECM mixture can comprise from about 5% to about 85% by weight of ECM material and from about 15% to about 95% by weight of a polymer material, such as, but not limited to, a biodegradable polyester. The presently disclosed anatomically-shaped porous ECM scaffolds can be formed, for example, using a three-dimensional (3D) printing process, an injection molding process, or any other process.Type: GrantFiled: June 24, 2016Date of Patent: March 12, 2024Assignee: JOHNS HOPKINS UNIVERSITYInventors: Warren Grayson, Jennifer Elisseeff, Ben Hung, Ethan Nyberg, Tram Nguyen
-
Patent number: 11911413Abstract: Pharmaceutical and veterinary compositions for oral administration comprising a therapeutically effective amount of at least one coxib together with a therapeutically effective amount of pentosan polysulfate or a pharmaceutically acceptable salt thereof are described. The compositions have application for the prophylaxis or treatment of pain and/or inflammation. There is also described a pharmaceutical or veterinary composition comprising a therapeutically effective amount of at least one coxib. The compositions in at least some forms may be lactose free and/or provided in a non-gelatin capsule. Further, there are provided methods for administration of a therapeutically effective amount of at least one coxib in combination with pentosan polysulfate or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of pain and/or inflammation.Type: GrantFiled: February 15, 2019Date of Patent: February 27, 2024Assignee: Proteobioactives Pty LimitedInventors: Peter Ghosh, Jack Edelman
-
Patent number: 11911504Abstract: A device for protecting neurons and reducing inflammation and adhesion formation following surgery is provided. Also provided is a method for protecting neurons and reducing inflammation and adhesion formation following surgery. The device includes a bioabsorbable substrate and a layer of an oxidation inhibitor mimicking the effects of superoxide dismutase and catalase enzymes located on a surface of the substrate. Oxidation inhibitors that may be used include EUK-8, EUK-134, EUK-189, and EUK-207 (a mimetic of superoxide dismutase/catalase), monosodium luminol or phenyl N-t-butylnitrone or an analog with similar anti-oxidant properties. The oxidation inhibitors reduce oxidative stress and trigger the subject's natural anti-oxidant and anti-inflammatory defenses, thereby reducing neuron death, loss of neuron connectivity, inflammation and scarring and restoring excitatory function of neurons.Type: GrantFiled: February 4, 2019Date of Patent: February 27, 2024Assignee: GALEN THERAPEUTICS LLCInventor: Tunc Toker
-
Patent number: 11896609Abstract: The present invention relates to a composition for treating inflammatory diseases comprising germanium telluride nanosheets coated with polyvinylpyrrolidone, and the nanosheets have excellent anti-inflammatory and thus are excellent in treating inflammatory bowel disease and psoriasis.Type: GrantFiled: August 23, 2022Date of Patent: February 13, 2024Assignee: Industry-Academic Cooperation FoundationInventors: Kyung-Hwa Yoo, Jun Ho Song, Yong-Beom Park, Sun-Mi Lee, Chin Hee Mun, Taejun Yoon
-
Patent number: 11889835Abstract: The present invention relates to a plant growth regulator of elevating anti-stress ability and use thereof. The plant growth regulator, which is consisted of Lactobacillus fermenting culture solution, has excellent thermostability and safety without any side effect, significantly elevating ability against biotic and abiotic stresses. Therefore, the Lactobacillus fermenting culture solution can be applied as the plant growth regulator or a use in preparation of a composition for elevating anti-stress ability of a plant.Type: GrantFiled: March 25, 2019Date of Patent: February 6, 2024Assignee: GENMONT BIOTECH INCORPORATIONInventors: Yi-Hsing Chen, Wan-Hua Tsai, Tsuei-Yin Huang, Hsiang-En Huang, Yu-Jen Hsu
-
Patent number: 11865225Abstract: Disclosed are a sustained-release injection formulation containing a biodegradable polymer double microcapsule that contains a conjugate of poly-L-lactic acid (hereinafter referred to as “PLLA”) filler and hyaluronic acid (hereinafter referred to as “HA”) and is capable of controlling the release rate of PLLA, and a method of preparing the same.Type: GrantFiled: November 6, 2020Date of Patent: January 9, 2024Assignee: GCS Co., Ltd.Inventor: Chang Sik Kim
-
Patent number: 11858884Abstract: Disclosed herein are methods for modulating an amount or activity of a gene or a gene product in a cell. The methods herein may comprise contacting a cell with a therapeutic agent assembled with a lipid composition, which lipid composition may comprise a dendrimer or dendron which may comprise one or more degradable diacyl group, in which may result in modulating the amount or activity of the gene or the gene product in the cell. The therapeutic agent modulating a gene or gene product in a cell may be sufficient to treat a disease or disorder in a subject. Further disclosed herein are pharmaceutical compositions, kits, and lipid compositions for modulating an amount or activity of a gene or a gene product in a cell.Type: GrantFiled: December 30, 2021Date of Patent: January 2, 2024Assignee: The Board of Regents of The University of Texas SystemInventors: Daniel J. Siegwart, Kejin Zhou
-
Patent number: 11850328Abstract: Provided herein are thermoresponsive polymer materials and methods of preparation and use thereof. In particular, materials are provided that cure upon exposure to physiologic conditions (e.g., human body temperature) and find use in, for example, orthopedic surgery, bone tissue engineering, and the repair of bone injuries and defects.Type: GrantFiled: November 14, 2017Date of Patent: December 26, 2023Assignee: Northwestern UniversityInventor: Guillermo A. Ameer
-
Patent number: 11844366Abstract: The present invention provides a tomato-derived composition comprising lycopene crystals at a concentration of at least 70% (w/w) and methylene chloride-insoluble material at a concentration of 10% (w/w) or less, wherein the size of said lycopene crystals is less than 1 micron. The present invention also encompasses a process for preparing said composition from tomato pulp.Type: GrantFiled: December 14, 2015Date of Patent: December 19, 2023Assignee: LYCORED LTD.Inventors: Tanya Sedlov, Tatyana Atlasman, Morris Zelkha
-
Patent number: 11844349Abstract: A method for removing or preventing a microbial growth, biofilm, biomass and/or mineral deposit on a hard surface inside an SO2 scrubber is disclosed. In particular, biocide compositions may be dosed in pulse or continuously for the reduction and prevention of biofilms on the hard surfaces inside an SO2 scrubber. A biocide composition disclosed here uses one or more non-oxidizing biocides, especially a mixture of one or more quaternary ammonium compounds and one or more other biocides.Type: GrantFiled: June 22, 2021Date of Patent: December 19, 2023Assignee: Ecolab USA Inc.Inventors: Junzhong Li, Chris Nagel, Laura Rice
-
Patent number: 11833256Abstract: The invention relates to compositions and methods as part of a pharmacotherapeutic strategy that targets the endochondral ossification process in a pharmacologically selective and site-specific manner. A variety of orthopedic pathologies are caused by or associated with generalized or local dysregulation of endochondral ossification, for example trauma to the bone growth plate or diaphysis can cause a serious imbalance in bone growth, leading to progressive deformity that today can only be treated surgically. Dysregulated endochondral ossification is also behind heterotopic ossification, which arises in soft tissues and causes pain, decrease in mobility and other clinical problems. The invention therefore provides RARy agonist and antagonist nanoparticle compositions for treating abnormal endochondral ossification and bone growth that can deliver robust local therapeutic control over a particular long bone's growth with a long-lasting effect.Type: GrantFiled: June 20, 2018Date of Patent: December 5, 2023Assignees: University of Maryland, Baltimore, The Children's Hospital of PhiladelphiaInventors: Masahiro Iwamoto, Michael Chorny
-
Patent number: 11826467Abstract: Microemulsions are disclosed herein that include a discontinuous internal phase comprising an aqueous solution encompassed within an internal emulsifier; a continuous oil phase encompassing the internal phase; and an external emulsifier encompassing the oil phase. Also disclosed are methods for the use of such microemulsions as drug delivery devices, and methods for treating glaucoma and reducing intraocular pressure.Type: GrantFiled: December 19, 2018Date of Patent: November 28, 2023Assignee: University of Tennessee Research FoundationInventors: Monica M. Jablonski, Mohamed Moustafa Ibrahim Moustafa
-
Patent number: 11813234Abstract: Method of treating hyperglycemia induced Red Blood Cell Disease/Dysfunction (RBCD) caused by generation of early and late glycation end products. Method of treating hemolytic anemia, smoldering hemolytic anemia, sickle cell anemia, hemorrhagic diseases, hemorrhagic stroke, hemorrhagic bleeding. Method of treating RBCD to prevent progression to diabetes associated vascular complications referred to as Syndrome X, particularly to prevent progression to chronic kidney disease, coronary vascular disease, and peripheral vascular disease.Type: GrantFiled: August 22, 2016Date of Patent: November 14, 2023Assignee: OXO TRANSLATIONAL SCIENCE GMBHInventors: Paiboon Maraprygsavan, Friedrich-Wilhelm Kuehne
-
Patent number: 11812746Abstract: A method of controlling a fungus infection in a plant susceptible to Botrytis infection is provided. The method comprising applying to the plant an effective amount of a phenylalanine or an analog thereof for controlling said fungus infection in the plant.Type: GrantFiled: August 28, 2017Date of Patent: November 14, 2023Assignee: THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER)Inventors: Michal Oren-Shamir, Moran Oliva, Efraim Lewinsohn, Noam Alkan, Yigal Elad
-
Patent number: 11801217Abstract: The present invention provides a biodegradable drug delivery composition comprising: (i) a mixture of at least three different block copolymers, wherein each block copolymer is: (a) a biodegradable triblock copolymer having the formula: Av-Bw-Ax wherein A is a polyester and B is polyethylene glycol and v and x are the number of repeat units from 1 to 3,000 and w is the number of repeat units from 3 to 300 and v=x or v?x; or (b) a biodegradable diblock copolymer having the formula: Cy-Az wherein A is a polyester and C is an end-capped polyethylene glycol and y and z are the number of repeat units with y=2 to 250 and z=1 to 3,000; and wherein the mixture comprises at least one (a) and at least one (b); and the weight ratio between (a) and (b) is 1:19 to 5:1; and (ii) at least one pharmaceutically active ingredient.Type: GrantFiled: July 17, 2018Date of Patent: October 31, 2023Assignee: MEDINCELL S.A.Inventors: Christophe Roberge, Anthony Rech, Jean-Manuel Cros, Myriam Abbassi, Adolfo López-Noriega, Lea Pebrel, Audrey Petit, Juliette Serindoux